Abstract
1 The effect of six months therapy with cimetidine (800 mg or 1600 mg/day) and subsequent withdrawal was studied in 19 patients with duodenal ulceration. 2 The overall rates of healing were 63% and 79% of patients after 3 and after 6 months of treatment respectively. The longer course (6 months) or the higher dose (1600 mg) did not result in significantly increased rates of ulcer healing. 3 Abrupt withdrawal of cimetidine resulted in the recurrence of severe symptoms in 15 patients (79%). 4 Pharmacokinetic studies showed the mean elimination half-life of cimetidine to be 100 +/- 25 min, the total body cimetidine clearance 652 +/- 223 ml/min, the mean volume of distribution at steady state 65 +/- 181 and the overall bioavailability 78%. 5 Long term cimetidine treatment does not result in drug accumulation or changes in its pharmacokinetic profile. 6 Inter-individual differences in clinical and endoscopic response to cimetidine cannot be explained by pharmacokinetic differences.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blackwood W. S., Maudgal D. P., Northfield T. C. Prevention by bedtime cimetidine of duodenal-ulcer relapse. Lancet. 1978 Mar 25;1(8065):626–627. doi: 10.1016/s0140-6736(78)91135-2. [DOI] [PubMed] [Google Scholar]
- Bodemar G., Norlander B., Fransson L., Walan A. The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease. Br J Clin Pharmacol. 1979 Jan;7(1):23–31. doi: 10.1111/j.1365-2125.1979.tb00892.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodemar G., Walan A. Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet. 1976 Jul 24;2(7978):161–164. doi: 10.1016/s0140-6736(76)92342-4. [DOI] [PubMed] [Google Scholar]
- Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
- Burland W. L., Duncan W. A., Hesselbo T., Mills J. G., Sharpe P. C., Haggie S. J., Wyllie J. H. Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol. 1975 Dec;2(6):481–486. doi: 10.1111/j.1365-2125.1975.tb00564.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fried J., Zietz S. Curve fitting by spline and Akima methods: possibility of interpolation error and its suppression. Phys Med Biol. 1973 Jul;18(4):550–558. doi: 10.1088/0031-9155/18/4/306. [DOI] [PubMed] [Google Scholar]
- Grahnén A., von Bahr C., Lindström B., Rosén A. Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol. 1979 Nov;16(5):335–340. doi: 10.1007/BF00605632. [DOI] [PubMed] [Google Scholar]
- Pedersen P. V., Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci. 1980 Apr;69(4):394–398. doi: 10.1002/jps.2600690408. [DOI] [PubMed] [Google Scholar]
- Randolph W. C., Osborne V. L., Walkenstein S. S., Intoccia A. P. High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-receptor antagonist, in blood and urine. J Pharm Sci. 1977 Aug;66(8):1148–1150. doi: 10.1002/jps.2600660825. [DOI] [PubMed] [Google Scholar]
- Walkenstein S. S., Dubb J. W., Randolph W. C., Westlake W. J., Stote R. M., Intoccia A. P. Bioavailability of cimetidine in man. Gastroenterology. 1978 Feb;74(2 Pt 2):360–365. [PubMed] [Google Scholar]